Related Experiment Videos
Rimantadine therapy of influenza A infection in mice
Abstract:
Eighty per cent of mice infected with a mouse-adapted strain of influenza virus died within 3 to 8 days after infection. Rimantadine given at maximum protective doses reduced mortality to 10%. This protection is dose related and can be demonstrated with doses from 4.5 to 24 mg per kg per day. Significant survival rates are shown by delaying treatment as long as 48 hr after infection. Lungs of treated mice have significantly less virus than those of controls at 24, 48, and 72 hr after infection. Antibody production as measured by hemagglutination inhibition is not different in treated and controlled mice. These results indicate that rimantadine is an effective prophylactic and therapeutic agent and that its activity is associated with decreased viral titers.
Insights
Rimantadine significantly reduced mortality in mice infected with influenza virus. This antiviral drug proved effective even when treatment was delayed, by lowering viral load without affecting antibody production.
Area of Science:
- Virology
- Pharmacology
- Immunology
Background:
- Influenza virus infections pose a significant public health threat.
- Mouse-adapted influenza strains are used to study viral pathogenesis and antiviral efficacy.
- Rimantadine is an antiviral medication historically used against influenza A.
Purpose of the Study:
- To evaluate the efficacy of rimantadine as a prophylactic and therapeutic agent against a mouse-adapted influenza virus.
- To determine the dose-response relationship and the impact of delayed treatment with rimantadine.
- To investigate the effect of rimantadine on viral titers and antibody production in infected mice.
Main Methods:
- Mice were infected with a mouse-adapted influenza strain.
- Rimantadine was administered at various doses (4.5–24 mg/kg/day) and treatment timings (including delayed administration up to 48 hours post-infection).
- Mortality rates, lung viral titers, and hemagglutination inhibition antibody responses were assessed.
Main Results:
- Rimantadine reduced mortality from 80% to 10% at maximum protective doses.
- Protection was dose-dependent and observed even with delayed treatment.
- Treated mice showed significantly lower lung viral titers at 24, 48, and 72 hours post-infection.
- Antibody production (hemagglutination inhibition) was not significantly different between treated and control groups.
Conclusions:
- Rimantadine demonstrates significant prophylactic and therapeutic efficacy against mouse-adapted influenza virus.
- The antiviral activity of rimantadine is linked to the reduction of viral titers in the lungs.
- Rimantadine's effectiveness is maintained even when treatment is initiated up to 48 hours after infection.